Amiselimod: A New Oral Agent in the Treatment of Multiple Sclerosis
Journal Title: UNKNOWN - Year 2017, Vol 23, Issue 3
Abstract
.
Authors and Affiliations
Ahmed Serkan Emekli
Keywords
Related Articles
- EP ID EP276707
- DOI 10.4274/tnd.90018
- Views 88
- Downloads 0
Intravenous Thrombolytic Therapy in Acute Stroke: Frequent Systemic Problems and Solutions
One of the most important reasons why the use of the intravenous (IV) tissue plasminogen activator (tPA), which is one of the key elements of acute ischemic stroke treatment, is not sufficiently widespread is the fact th...
Response of Treatment in Patients with Primary Headaches and Hypertension: A Prospective Observational Pilot Study
Objective: To determine the priority in the treatment of patients with primary headaches accompanied by high blood pressure. In our study, we investigated whether there was a relationship between the decline in headache...
Subcutaneous Ofatumumab in Patients with Relapsing-remitting Multiple Sclerosis
.
Chronic Progressive Neuro-Behçet’s Disease: Magnetic Resonance Spectroscopy and Apparent Diffusion Coefficient Findings
.
Evaluation of Seizure After Stroke in Stroke Unit
Objective: Patients with stroke may experience epileptic seizures as acute phase (usually defined as the first 15 days) or late phase complications. Risk factors are young age, male sex, cortical involvement and hemorrha...